Total Payments
$11,635
2024 Payments
$233.01
Companies
8
Transactions
27
Medicare Patients
359
Medicare Billing
$35,665
Payment Breakdown by Category
Research$9,429 (81.0%)
Food & Beverage$1,557 (13.4%)
Consulting$650.00 (5.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9,429 | 10 | 81.0% |
| Food and Beverage | $1,557 | 16 | 13.4% |
| Consulting Fee | $650.00 | 1 | 5.6% |
Payments by Type
Research
$9,429
10 transactions
General
$2,207
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $10,079 | 11 | $0 (2019) |
| AbbVie Inc. | $559.86 | 6 | $0 (2020) |
| Boston Scientific Corporation | $432.58 | 4 | $0 (2024) |
| Genentech USA, Inc. | $260.34 | 2 | $0 (2018) |
| Celgene Corporation | $133.78 | 1 | $0 (2019) |
| INTERCEPT PHARMACEUTICALS, INC. | $115.58 | 1 | $0 (2022) |
| Exact Sciences Corporation | $44.01 | 1 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $10.50 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $233.01 | 3 | Boston Scientific Corporation ($189.00) |
| 2022 | $115.58 | 1 | INTERCEPT PHARMACEUTICALS, INC. ($115.58) |
| 2020 | $33.78 | 2 | AbbVie Inc. ($33.78) |
| 2019 | $8,588 | 13 | NOVARTIS PHARMACEUTICALS CORPORATION ($7,804) |
| 2018 | $2,546 | 7 | Novartis Pharmaceuticals Corporation ($2,275) |
| 2017 | $119.54 | 1 | BOSTON SCIENTIFIC CORPORATION ($119.54) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/29/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $44.01 | General |
| Category: Oncology | ||||||
| 04/26/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $126.50 | General |
| Category: General - Biliary Devices_ENDO | ||||||
| 04/26/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $62.50 | General |
| Category: General - Biliary Devices_ENDO | ||||||
| 11/30/2022 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $115.58 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 10/28/2020 | AbbVie Inc. | HUMIRA (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: IMMUNOLOGY | ||||||
| 10/20/2020 | AbbVie Inc. | HUMIRA (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: IMMUNOLOGY | ||||||
| 07/25/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $144.98 | General |
| Category: Immunology | ||||||
| 06/14/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | SANDOSTATIN (Drug) | — | In-kind items and services | $3,142.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: ONCOLOGY | ||||||
| 05/30/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $121.13 | General |
| Category: Immunology | ||||||
| 05/20/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | SANDOSTATIN (Drug) | — | In-kind items and services | $837.88 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: ONCOLOGY | ||||||
| 04/15/2019 | Boston Scientific Corporation | ORISE (Device) | Food and Beverage | In-kind items and services | $124.04 | General |
| Category: POLYPECTOMY | ||||||
| 03/25/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | SANDOSTATIN (Drug) | — | In-kind items and services | $957.57 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: ONCOLOGY | ||||||
| 03/14/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $142.69 | General |
| Category: Immunology | ||||||
| 03/14/2019 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $133.78 | General |
| 01/23/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | SANDOSTATIN LAR (Drug) | — | Cash or cash equivalent | $650.00 | Research |
| Study: OUTCOMES RESEARCH • Category: ONCOLOGY | ||||||
| 01/17/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | SANDOSTATIN (Drug) | — | In-kind items and services | $1,117.17 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: ONCOLOGY | ||||||
| 01/16/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | SANDOSTATIN (Drug) | — | In-kind items and services | $286.50 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: ONCOLOGY | ||||||
| 01/15/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $117.28 | General |
| Category: Immunology | ||||||
| 01/02/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | SANDOSTATIN LAR (Drug) | — | Cash or cash equivalent | $812.50 | Research |
| Study: OUTCOMES RESEARCH • Category: ONCOLOGY | ||||||
| 10/24/2018 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $110.34 | General |
| Category: Immunology | ||||||
| 10/11/2018 | Genentech USA, Inc. | Perjeta (Biological) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: BioOncology | ||||||
| 08/25/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | SANDOSTATIN LAR (Drug) | — | Cash or cash equivalent | $650.00 | Research |
| Study: OUTCOMES RESEARCH • Category: ONCOLOGY | ||||||
| 08/01/2018 | Ipsen Biopharmaceuticals, Inc | Somatuline Depot (Drug) | Food and Beverage | In-kind items and services | $10.50 | General |
| Category: Oncology/Endocrinology | ||||||
| 07/24/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | SANDOSTATIN LAR (Drug) | — | Cash or cash equivalent | $325.00 | Research |
| Study: OUTCOMES RESEARCH • Category: ONCOLOGY | ||||||
| 07/03/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | SANDOSTATIN LAR (Drug) | — | Cash or cash equivalent | $650.00 | Research |
| Study: OUTCOMES RESEARCH • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $6,341 | 5 |
| OUTCOMES RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $3,088 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 32 | 36 | $12,546 | $2,138 |
| 2022 | 1 | 44 | 55 | $15,950 | $4,208 |
| 2021 | 7 | 187 | 240 | $110,995 | $20,304 |
| 2020 | 3 | 96 | 123 | $40,770 | $9,015 |
Total Patients
359
Total Services
454
Medicare Billing
$35,665
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 16 | 19 | $7,961 | $1,404 | 17.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 16 | 17 | $4,585 | $734.48 | 16.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 44 | 55 | $15,950 | $4,208 | 26.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 69 | 106 | $30,740 | $8,483 | 27.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 24 | 36 | $15,200 | $4,445 | 29.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 16 | 16 | $10,560 | $2,570 | 24.3% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 27 | 27 | $11,070 | $2,485 | 22.4% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 12 | 12 | $22,920 | $1,433 | 6.3% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 11 | 12 | $20,040 | $797.13 | 4.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 28 | 31 | $465.00 | $90.38 | 19.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 63 | 83 | $24,070 | $5,394 | 22.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 16 | 23 | $9,890 | $2,080 | 21.0% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 17 | 17 | $6,810 | $1,540 | 22.6% |
About Dr. Michelle Kim, MD
Dr. Michelle Kim, MD is a Gastroenterology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851319651.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michelle Kim, MD has received a total of $11,635 in payments from pharmaceutical and medical device companies, with $233.01 received in 2024. These payments were reported across 27 transactions from 8 companies. The most common payment nature is "" ($9,429).
As a Medicare-enrolled provider, Kim has provided services to 359 Medicare beneficiaries, totaling 454 services with total Medicare billing of $35,665. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location New York, NY
- Active Since 07/18/2006
- Last Updated 02/22/2019
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1851319651
Products in Payments
- SANDOSTATIN (Drug) $6,341
- SANDOSTATIN LAR (Drug) $3,738
- Humira (Biological) $526.08
- Perjeta (Biological) $150.00
- ORISE (Device) $124.04
- AXIOS (Device) $119.54
- OCALIVA (Drug) $115.58
- Xolair (Biological) $110.34
- Cologuard Collection Kit (Device) $44.01
- HUMIRA (Biological) $33.78
- Somatuline Depot (Drug) $10.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in New York
Arthur Kornbluth, Md, MD
Gastroenterology — Payments: $2.4M
Gastroenterology $2.4M
Dr. David Carr-Locke, Md Frcp Facg Masge, MD FRCP FACG MASGE
Gastroenterology — Payments: $2.3M
Gastroenterology $2.3M
Jean-Frederic Colombel, M.d, M.D
Gastroenterology — Payments: $1.1M
Gastroenterology $1.1M
Dr. Bruce Sands, Md, MD
Gastroenterology — Payments: $1.0M
Gastroenterology $1.0M
Ellen Scherl, Md, MD
Gastroenterology — Payments: $880,329
Gastroenterology $880,329
Sonal Kumar, Md, MD
Gastroenterology — Payments: $769,554
Gastroenterology $769,554